Welcome back, traders! After a phenomenal run in 2025, we aren’t slowing down. Our goal is to bring that same winning energy and precise execution into 2026. To make sure you’re getting the most out of our research, we’ve launched additional platforms so you can get firsthand access to everything we’re doing. You can even head over to the iOS App Store and download ChartSwipe or subscribe to our Powerhouse newsletters—visit powerhouse.substack.com to get direct access to our email updates and community!
This week, we are merging the ultimate disciplines of speculation: the stringent fundamental requirements of leading stocks with the ruthless, price-action tape reading of the market’s greatest pioneers. The tape is currently painting a complex macroeconomic picture that requires supreme patience and precise execution.
Here is how we are reading the market right now, and the specific setups we are stalking.
The Macro Tape: Reading the Economic Footprints
You never argue with the tape. Right now, the Federal Reserve has held rates steady in the 3.50% to 3.75% range.However, Brent crude is trading near $108 per barrel, creating a massive energy supply shock that is rippling through the data.
Because there is no Federal Open Market Committee (FOMC) scheduled for May, every single high-impact data release carries immense weight. The absolute pivot point for the broader market this week arrives on Friday, May 8, when the U.S. releases the non-farm payroll (NFP) data for April. We are watching closely to see if the labor market is genuinely re-accelerating or just absorbing seasonal noise. Do not anticipate the Friday data; wait for the market’s volume-backed reaction.+2
High-Potential Plays & Earnings Setups
Williams Companies (NYSE: WMB) – The Energy Breakout Watch
- The Tape: With Brent crude holding near $108, energy infrastructure remains a leading group. True market leaders emerge from strong sectors.
- The Catalyst: Williams is scheduled to announce its first-quarter 2026 financial results after the market closes on Monday, May 4.
- The Setup: We are looking for a breakaway gap or a high-volume surge post-earnings. If institutional money steps in and drives the price up on volume that is at least 50% above average, it confirms the fundamental strength. Never buy the whisper; buy the institutional reaction.
Cardiol Therapeutics (NASDAQ: CRDL) – News & Milestones
For our biotechnology watchers, we are tracking the fundamental milestones of Cardiol Therapeutics strictly through the lens of recent corporate developments.
$CRDL FEATURED IN THE WALLSTVAULT.COM
- The News: On April 28, the company announced the planned activation of up to seven additional clinical centers for its Phase III MAVERIC trial, which will bring the total number of sites to 25.
- The Data: Patient enrollment in the MAVERIC trial has officially reached 75%. The company anticipates that target recruitment will be completed by the end of Q2 2026.
- The Fundamentals: The FDA has previously granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis. Furthermore, Cardiol currently holds more cash than debt on its balance sheet, which is a critical advantage for funding ongoing clinical operations.
- The Setup: We are simply monitoring the tape. Let the price action and volume dictate if and when these fundamental milestones attract sustained institutional accumulation. Do not speculate; wait for the chart to confirm.
The Golden Rules for the Week Remember the laws of the trade: cutting losses is your only insurance policy, and averaging down on a losing position is a cardinal sin. With major jobs data dropping on Friday, expect volatility. Keep your watchlists tight, demand volume confirmation on every breakout, and let the market prove its direction before you commit heavy capital.
See you on the tape.
Becoming a consistent trader is not easy.
Most fail.
At News On Wall Street we have a program.
Nothing is guaranteed but, we are opening the doors!
Text us at 844-722-9743.
LEGAL COMPLIANCE & DISCLOSURES
NOT FINANCIAL ADVICE – EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY All information provided by News On Wall Street (the “Publisher”) is strictly for educational and informational purposes only. Nothing contained herein constitutes, or is intended to constitute, investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. The Publisher is not a registered investment adviser, broker-dealer, or financial planner with any regulatory agency. We do not provide personalized investment recommendations and have no fiduciary duty to any reader or subscriber.
You should consult with a qualified, licensed financial professional (such as a registered investment adviser or broker-dealer) who can assess your individual financial situation, risk tolerance, investment objectives, and tax consequences before making any investment decision. Investing in micro-cap biotechnology stocks like Cardiol Therapeutics ($CRDL) carries extreme risk, including the potential for total loss of principal. Biotech companies frequently experience total failure of clinical programs, regulatory rejection, massive dilution, delisting, or bankruptcy. Volatility can be extreme, with shares sometimes moving 50% or more in a single day on news events.
HIGH-RISK WARNING SPECIFIC TO BIOTECHNOLOGY INVESTING Biotechnology investing is inherently binary and speculative. Most clinical-stage companies never generate profits, never receive regulatory approval, and ultimately result in significant or total investor losses. Factors that could cause actual results to differ materially from any expectations expressed here include (but are not limited to): failure of Phase II or Phase III clinical trials (such as the ARCHER or MAVERIC trials referenced), delays or denial of FDA or other regulatory approvals, manufacturing issues, competition from larger pharmaceutical companies, intellectual property challenges, dilution from future financings, changes in healthcare policy, clinical safety concerns, adverse events, inability to secure additional funding, loss of key personnel, and general market or economic conditions. Past clinical data is not a guarantee of future success in larger trials or commercialization.
FORWARD-LOOKING STATEMENTS SAFE HARBOR This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “project,” “may,” “will,” “could,” “should,” “potential,” “intend,” “forecast,” “target,” or similar expressions.
All forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve risks and uncertainties. These statements speak only as of the date they are made, and the Publisher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those expressed or implied due to the numerous risks outlined above and in Cardiol’s SEC filings (10-K, 10-Q, 8-K, etc.). Nothing in this report is a guarantee of future performance, clinical success, regulatory approval, commercialization, or stock price appreciation.
SEC RULE 17(b) DISCLOSURE (PAID PROMOTION / AWARENESS CAMPAIGN) News On Wall Street (the “Publisher”) has been compensated $100,000 in cash by Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) for the creation, distribution, and ongoing awareness efforts related to this report and associated content. This compensation covers the period from April 7, 2026, through May 27, 2026. The payment was made directly by the Company (or its agents) to the Publisher and constitutes a material conflict of interest.
This entire communication is a paid advertisement / sponsored awareness campaign. The Publisher was compensated specifically to publish, publicize, and circulate information regarding Cardiol’s securities. Under Section 17(b) of the Securities Act of 1933, this disclosure is required. Investors must assume that the Publisher’s objectivity is influenced by this relationship. THIS IS NOT INDEPENDENT RESEARCH. It is commissioned, paid-for promotional material. The Publisher is not acting as an independent analyst and does not claim to provide unbiased or impartial analysis.
CONFLICT OF INTEREST DISCLOSURE The Publisher and/or its principals, affiliates, officers, directors, employees, family members, or other associated parties may currently hold, or may in the future purchase or sell, positions in Cardiol Therapeutics ($CRDL) or any other securities mentioned without prior or subsequent notice to readers. The Publisher may buy or sell shares at any time, including before, during, or after the distribution of this report. This creates an inherent conflict of interest.
INFORMATION SOURCES, ACCURACY, AND LIABILITY Information in this report is derived from public sources believed to be reliable (Company press releases, SEC filings, etc.). However, the Publisher makes no representation or warranty as to the accuracy, completeness, or timeliness of any information provided. To the fullest extent permitted by law, News On Wall Street, its officers, directors, and affiliates shall not be liable for any direct, indirect, or consequential damages arising out of the use of this report, including trading losses or loss of profits.
PERFORM YOUR OWN DUE DILIGENCE (DYOR) Always conduct your own thorough independent research. Review Cardiol’s latest SEC filings at www.sec.gov, consult multiple independent sources, and speak with your own financial and legal advisors before investing. Do not rely solely on any paid promotional material.
By continuing to read or act upon any information provided by News On Wall Street, you acknowledge that you have read, understood, and agreed to this full Legal Compliance & Disclosures section in its entirety.
